Classifying risk factors for dyskinesia in Parkinson's disease

被引:82
|
作者
Sharma, J. C. [1 ]
Bachmann, C. G. [2 ]
Linazasoro, G. [3 ]
机构
[1] Univ Nottingham, Sherwood Forest Hosp NHS Trust, Nottingham NG7 2RD, England
[2] Univ Gottingen, Dept Clin Neurophysiol, Gottingen, Germany
[3] Fdn Inbiomed, Policlin Gipuzkoa, Ctr Invest Parkinson, San Sebastian, Spain
关键词
Dyskinesia; Levodopa dose per kilogram body weight; Risk factors; Parkinson's disease; LEVODOPA-INDUCED DYSKINESIAS; RECEPTOR GENE POLYMORPHISM; MOTOR FLUCTUATIONS; L-DOPA; BODY-WEIGHT; ONSET AGE; MOLECULAR-MECHANISMS; CLINICAL-FEATURES; ASSOCIATION; THERAPY;
D O I
10.1016/j.parkreldis.2010.06.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia. Methods: We conducted literature search to identify and classifying risk factors into groups (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable. Results: Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor. Conclusion: Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia. (C) 2010 Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码:490 / 497
页数:8
相关论文
共 50 条
  • [41] The effect of dyskinesia on gait in Parkinson's disease
    Danoudis, M.
    McGinley, J.
    Iansek, R.
    MOVEMENT DISORDERS, 2013, 28 : S365 - S365
  • [42] Placebo influences on dyskinesia in Parkinson's disease
    Goetz, C. G.
    Laska, E.
    Hicking, C.
    Damier, P.
    Mueller, T.
    Nutt, J.
    Olanow, C. W.
    Rascol, O. O.
    Russ, H.
    MOVEMENT DISORDERS, 2007, 22 : S243 - S244
  • [43] Surgical treatment of dyskinesia in Parkinson's disease
    Munhoz, Renato P.
    Cerasa, Antonio
    Okun, Michael S.
    FRONTIERS IN NEUROLOGY, 2014, 5
  • [44] Motor fluctuations and dyskinesia in Parkinson's disease
    Nutt, JG
    PARKINSONISM & RELATED DISORDERS, 2001, 8 (02) : 101 - 108
  • [45] Placebo influences on dyskinesia in Parkinson's disease
    Goetz, Christopher G.
    Laska, Eugene
    Hicking, Christine
    Damier, Philippe
    Mueller, Thomas
    Nutt, John
    Olanow, C. Warren
    Rascol, Olivier
    Russ, Hermann
    MOVEMENT DISORDERS, 2008, 23 (05) : 700 - 707
  • [46] Therapy found for Parkinson's disease dyskinesia
    Bradbury, J
    LANCET, 2003, 361 (9370): : 1712 - 1712
  • [47] Risk factors in periodontitis and classifying the disease
    Meisel, P
    Kocher, T
    EUROPEAN JOURNAL OF ORAL SCIENCES, 2003, 111 (03) : 280 - 281
  • [48] Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease
    Siderowf, Andrew
    Jennings, Danna
    Connolly, James
    Doty, Richard L.
    Marek, Kenneth
    Stern, Matthew B.
    MOVEMENT DISORDERS, 2007, 22 (15) : 2249 - 2255
  • [49] Mitochondrial DNA polymorphisms as risk factors for Parkinson’s disease and Parkinson’s disease dementia
    Jaana Autere
    Jukka S. Moilanen
    Saara Finnilä
    Hilkka Soininen
    Arto Mannermaa
    Päivi Hartikainen
    Merja Hallikainen
    Kari Majamaa
    Human Genetics, 2004, 115 : 29 - 35
  • [50] Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia
    Autere, J
    Moilanen, JS
    Finnilä, S
    Soininen, H
    Mannermaa, A
    Hartikainen, P
    Hallikainen, M
    Majamaa, K
    HUMAN GENETICS, 2004, 115 (01) : 29 - 35